Experts from the University of of Dundee's Centre for Targeted Protein Degradation (CeTPD), working with Boehringer Ingelheim ...

The latest trial over claims that the discontinued heartburn drug Zantac causes cancer ended with a hung jury on Wednesday, ...

Boehringer Ingelheim announced today that the FIBRONEERTM-IPF trial met its primary endpoint, which was the absolute change ...

Boehringer Ingelheim has ended a decade of industrywide failures in idiopathic pulmonary fibrosis (IPF) by reporting a phase ...

On Wednesday, a jury in Cook County Circuit Court in Illinois ended in a mistrial in a case against Zantac manufacturer ...

The positive phase 3 results showed improved lung function with nerandomilast vs placebo at 52 weeks in idiopathic pulmonary ...

The trial met its primary endpoint, showing a meaningful objective response rate and a tolerable safety profile for ...

Boehringer Ingelheim’s investigational compound nerandomilast, which targets the PDE4B enzyme involved in fibrosis and ...

Boehringer Ingelheim Pharma GmbH & Co. KG has synthesized NADPH oxidase 4 (NOX4) inhibitors reported to be useful for the treatment of atherosclerosis, cancer, pulmonary hypertension, inflammatory ...

Boehringer Ingelheim today announced that the FIBRONEER-IPF trial met its primary endpoint, which was the absolute change ...

An Illinois mistrial involving the recalled medication Zantac is the latest court decision involving the recalled drug, but ...

Boehringer Ingelheim pivotal phase-III FIBRONEER-IPF study of nerandomilast meets primary endpoint: Ingelheim, Germany Tuesday, September 17, 2024, 13:00 Hrs [IST] Boehringer Inge ...